SLXM-2, a derivative of cyclophosphamide: Mechanism of growth inhibition on hepatocarcinoma 22 cells

Anti-Cancer Drugs

Volumn 19, Issue 2, 2008, Pages 167-174

  Pang, Li Ping ^a   Huang, Wei ^a   Sun, Qi ^a   Guo, Wei ^a   Li, Run Tao ^a   Cui, Jing Rong ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Cell cycle arrest; Cyclophosphamide; Derivative; Hepatocarcinoma H 22; Lethal dose 50; Leukocytotoxic effect

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYCLOPHOSPHAMIDE DERIVATIVE; SLXM 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CONTROLLED STUDY; FLOW CYTOMETRY; GROWTH INHIBITION; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CDC2-CDC28 KINASES; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN B; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; G2 PHASE; GENE EXPRESSION; INJECTIONS, INTRAPERITONEAL; LEUKOCYTE COUNT; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED ICR; MOLECULAR STRUCTURE; PIPERAZINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; S PHASE; WEIGHT LOSS;

EID: 37849050751     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3282f2885f     Document Type: Article

References (33)

1. American Cancer Society. Cancer facts and figures, The American Cancer Society's Publication. Washington: American Cancer Society; 2004.
2. Colvin M, Chabner BA. Alkylating agents. In: Chabner BA, Collins JM, editors. Cancer chemotherapy: principles and practice. Philadelphia: Lippincott; 1991. pp. 276-313.
3. Wu CM, Li XY, Huang TH. Anti-tumor effect of pEgr-IFNgamma gene-radiotherapy in B16 melanoma-bearing ice. World J Gastroenterol 2004; 10:3011-3015.
4. Frieddman OM, Myles A, Colin M. Cyclophosphamide and related phosphoramide mustards: current status and future prospects. Adv Cancer Chemother 1979; 1:143.
5. Stec WJ. Cyclophosphamide and its congeners. Organophosphorus Chem 1982; 13:145.
6. Bonadonna G, Moliterni A, Zambetti M. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 2005; 330:217-222.
7. Erol K, Baltali E, Altundag K. Neoadjuvant chemotherapy with cyclophosphamide, mitoxantrone, and 5-fluorouracil in locally advanced breast cancer. Onkologie 2005; 28:81-85.
8. Cascallo M, Alemany R. Adenovirus-mediated gene transfer to tumor cells. Methods Mol Biol 2004; 246:121-138.
9. Kuwashima N, Kageyama S, Eto Y, Urashima M. CD40 ligand immunotherapy in cancer: an efficient approach. Leuk Lymphoma 2001; 42:1367-1377.
10. Sun Q, Li RT, Guo W, Cui JR, Cheng TM, Ge ZM. Novel class of cyclophosphamide prodrug: cyclophosphamide spiropiperaziniums (CPSP). Bioorg Med Chem Lett 2006; 16:3727-3730.
11. Petri M. Cyclophosphamide: new approaches for systemic lupus erythematosus. Lupus 2004; 13:366-371.
12. Wang XM, Ju GZ, Fu HQ, Mei SJ, Liu SJ. Changes in mRNA levels of cyclin B1 and Cdc2 of EL-4 cells after 4Gy X-rays irradiation. J Radiat Res Radiat Process 2004; 22:43-46.
13. Sharma R, Kline R. Chemosensitivity assay in mice prostate tumor: preliminary report of flow cytometry, DNA fragmentation, ion ratiometric methods of anti-neoplastic drug monitoring. Cancer Cell Int 2004; 4:3.
14. Stewart ZA, Westfall MD, Pietenpol JA. Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol Sci 2003; 24:139-145.
15. Will R. Cancer and the role of cell cycle check points. Rev Undergrad Res 2002; 1:1-7.
16. Charles JS. The pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000; 60:3689-3695.
17. 2/M transition. Biochim Biophys Acta 2001; 1519:1-12.
18. 2-phase DNA-damage checkpoint. Trends Cell Biol 2000; 10:296-303.
19. Galaktionov K, Jessus C, Beach D. Raf1 interaction with Cdc25 phosphatase ties mitogenic signal transduction to cell cycle activation. Genes Dev 1995; 9:1046-1058.
20. Jin P, Hardy S, Morgan DO. Nuclear localization of cyclin B1 controls mitotic entry after DNA damage. J Cell Biol 1998; 141:875-885.
21. Lukas J, Lukas C, Bartek J. Mammalian cell cycle checkpoints: signaling pathways and their organization in space and time. DNA Repair 2004; 3:997-1007.
22. Arion D, Meijer L, Brizuela L, Beach D. Cdc2 is a component of the M phase-specific histone H1 kinase: evidence for identity with MPF. Cell 1998; 55:371-378.
23. cdc2 and a possible mechanism for its periodic activation. Cell 1989; 57:253-263.
24. Dunphy WG, Brizuela L, Beach D, Newport J. The Xenopus Cdc2 protein is a component of MPF, a cytoplasmic regulator of mitosis. Cell 1988; 54:423-431.
25. Holloway SL, Glotzer M, King RW, Murray AW. Anaphase is initiated by proteolysis rather than by the inactivation of maturation-promoting factor. Cell 1993; 73:1393-1402.
26. Foisner R, Gerace L. Integral membrane proteins of the nuclear envelope interact with lamins and chromosomes, and binding is modulated by mitotic phosphorylation. Cell 1993; 73:1267-1279.
27. Peter M, Nakagawa J, Dorée M, Labbé JC, Nigg EA. In vitro disassembly of the nuclear lamina and M phase-specific phosphorylation of lamins by Cdc2 kinase. Cell 1993; 61:591-602.
28. Murray AW, Kirschner MW. Dominoes and clocks: the union of two views of the cell cycle. Science 1989; 246:614-621.
29. Gould KL, Nurse P. Tyrosine phosphorylation of the fission Cdc2 protein kinase regulates entry into mitosis. Nature 1989; 342:39-45.
30. cdc25 mitotic inducer in fission yeast. Nature 1990; 344:549-552.
31. Alfa CE, Ducommun B, Beach D, Hyams JS. Distinct nuclear and spindle pole body populations of cyclin-cdc2 in fission yeast. Nature 1990; 347:680-682.
32. Fisher RP, Morgan DO. A novel cyclin associates with M015/CDK7 to form the CDK-activating kinase. Cell 1994; 78:713-724.
33. Slavin RE, Millan JC, Mullins GM. Pathology of high dose intermittent cyclophosphamide therapy. Hum Pathol 1975; 6:693-699.